• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21.

作者信息

Zhou Xia, Wu Hongying, Hao Lumei, Wei Liyan, Li Xuemei, Yin Junjing, Yu Qianru, Xie Zhanzhi, Zhong Yuping

机构信息

Hematology Department, Qingdao Hospital, University of Health and Rehabilitation Science (Qingdao Municipal Hospital), Qingdao, Shandong 266011, China.

Sanofi-Aventis China Investment Co., Ltd., Beijing 100124, China.

出版信息

Chin Med J (Engl). 2025 Apr 5;138(7):871-873. doi: 10.1097/CM9.0000000000003435. Epub 2025 Jan 14.

DOI:10.1097/CM9.0000000000003435
PMID:39809712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11970805/
Abstract
摘要

相似文献

1
Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21.1q21获得/扩增的复发/难治性多发性骨髓瘤患者的治疗疗效
Chin Med J (Engl). 2025 Apr 5;138(7):871-873. doi: 10.1097/CM9.0000000000003435. Epub 2025 Jan 14.
2
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.周期蛋白依赖性激酶亚单位 1B 的核表达可预测硼替佐米治疗复发/难治性多发性骨髓瘤患者的不良预后。
Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.
3
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.伊沙妥昔单抗联合卡非佐米和地塞米松治疗 1q21 异常的复发/难治性多发性骨髓瘤患者：3 期 IKEMA 研究的长期结果。
Hematol Oncol. 2024 Mar;42(2):e3258. doi: 10.1002/hon.3258.
4
Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.达雷妥尤单抗治疗伴有 1q21 增益的初诊多发性骨髓瘤患者的疗效。
Int J Hematol. 2024 Jul;120(1):71-79. doi: 10.1007/s12185-024-03760-w. Epub 2024 Mar 29.
5
Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.1q21染色体臂扩增的复发/难治性多发性骨髓瘤患者中与基于达雷妥尤单抗治疗相关的不良结局：一项单中心回顾性研究经验
Ann Hematol. 2022 Dec;101(12):2777-2779. doi: 10.1007/s00277-022-04978-6. Epub 2022 Sep 15.
6
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.达雷妥尤单抗治疗高危复发/难治性多发性骨髓瘤患者：染色体 1q21 获得/扩增和 GEP70 状态对预后的不良影响。
Br J Haematol. 2020 Apr;189(1):67-71. doi: 10.1111/bjh.16292. Epub 2019 Dec 9.
7
[Clinical and biological characteristics multiple myeloma with 1q21 amplification].伴有1q21扩增的多发性骨髓瘤的临床和生物学特征
Zhonghua Yi Xue Za Zhi. 2016 Mar 1;96(8):615-9. doi: 10.3760/cma.j.issn.0376-2491.2016.08.007.
8
Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma.多发性骨髓瘤中1q21染色体臂的获得/扩增
Cancers (Basel). 2021 Jan 12;13(2):256. doi: 10.3390/cancers13020256.
9
Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.1q21 在多发性骨髓瘤中的作用：从发病机制到可能的治疗靶点。
Cells. 2021 Jun 1;10(6):1360. doi: 10.3390/cells10061360.
10
The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.1q21 获得/扩增在新诊断多发性骨髓瘤中的预后影响：一项基于中国单中心的回顾性研究。
Ann Hematol. 2025 Jan;104(1):503-513. doi: 10.1007/s00277-024-06164-2. Epub 2025 Jan 4.

本文引用的文献

1
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.isatuximab联合卡非佐米-地塞米松对比卡非佐米-地塞米松治疗复发多发性骨髓瘤患者（IKEMA）：一项3期随机对照试验的总生存分析
Lancet Haematol. 2024 Oct;11(10):e741-e750. doi: 10.1016/S2352-3026(24)00148-0. Epub 2024 Jul 24.
2
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.isatuximab治疗的复发/难治性多发性骨髓瘤患者按1q21+状态划分的主要结局：来自ICARIA-MM和IKEMA的亚组分析
Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.
3
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.伊沙佐米、来那度胺和地塞米松用于复发或难治性多发性骨髓瘤患者的TOURMALINE-MM1 III期试验的最终总生存分析
J Clin Oncol. 2021 Aug 1;39(22):2430-2442. doi: 10.1200/JCO.21.00972. Epub 2021 Jun 11.
4
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.isatuximab、卡非佐米和地塞米松用于复发多发性骨髓瘤（IKEMA）：一项多中心、开放标签、随机3期试验
Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4.
5
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.ICARIA-MM 研究中伴有高危细胞遗传学的复发/难治性多发性骨髓瘤患者的亚组分析。
Br J Haematol. 2021 Jul;194(1):120-131. doi: 10.1111/bjh.17499. Epub 2021 May 25.
6
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.Elotuzumab、来那度胺和地塞米松治疗 RRMM：来自 3 期随机 ELOQUENT-2 研究的最终总生存结果。
Blood Cancer J. 2020 Sep 4;10(9):91. doi: 10.1038/s41408-020-00357-4.
7
Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis.中国城市地区多发性骨髓瘤的患病率和发病率：一项基于全国人口的分析。
Front Oncol. 2020 Jan 24;9:1513. doi: 10.3389/fonc.2019.01513. eCollection 2019.
8
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.达雷妥尤单抗治疗高危复发/难治性多发性骨髓瘤患者：染色体 1q21 获得/扩增和 GEP70 状态对预后的不良影响。
Br J Haematol. 2020 Apr;189(1):67-71. doi: 10.1111/bjh.16292. Epub 2019 Dec 9.
9
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.埃罗妥珠单抗联合泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.
10
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.伊沙佐米可显著延长高危复发/难治性骨髓瘤患者的无进展生存期。
Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.